4.5 Article

Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer

Journal

CANCER SCIENCE
Volume 112, Issue 3, Pages 1141-1149

Publisher

WILEY
DOI: 10.1111/cas.14785

Keywords

cervical cancer; E545K mutation; PI3K inhibitor; PIK3CA gene; pyrrole-imidazole polyamide-seco-CBI

Categories

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology [JP25830092]
  2. Japan Society for the Promotion of Science [JP16H01579, JP17H03602, JP26290060]
  3. Princess Takamatsu Cancer Research Fund
  4. Takeda Science Foundation

Ask authors/readers for more resources

The novel pyrrole-imidazole polyamide-seco-CBI conjugate P3AE5K effectively targeted PIK3CA mutant cells in cervical cancer, demonstrating strong cytotoxicity and the potential to be a promising new drug candidate.
PIK3CA is the most frequently mutated oncogene in cervical cancer, and somatic mutations in the PIK3CA gene result in increased activity of PI3K. In cervical cancer, the E545K mutation in PIK3CA leads to elevated cell proliferation and reduced apoptosis. In the present study, we designed and synthesized a novel pyrrole-imidazole polyamide-seco-CBI conjugate, P3AE5K, to target the PIK3CA gene bearing the E545K mutation, rendered possible by nuclear access and the unique sequence specificity of pyrrole-imidazole polyamides. P3AE5K interacted with double-stranded DNA of the coding region containing the E545K mutation. When compared with conventional PI3K inhibitors, P3AE5K demonstrated strong cytotoxicity in E545K-positive cervical cancer cells at lower concentrations. PIK3CA mutant cells exposed to P3AE5K exhibited reduced expression levels of PIK3CA mRNA and protein, and subsequent apoptotic cell death. Moreover, P3AE5K significantly decreased the tumor growth in mouse xenograft models derived from PIK3CA mutant cells. Overall, the present data strongly suggest that the alkylating pyrrole-imidazole polyamide P3AE5K should be a promising new drug candidate targeting a constitutively activating mutation of PIK3CA in cervical cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available